Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates

Hypertension

Volumn 27, Issue 6, 1996, Pages 1341-1345

  Bartholomeusz, Briony ^a   Hardy, Kenneth J ^a   Nelson, Angela S ^a   Phillips, Paddy A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

bosentan; cyclosporine; endothelin; primates; rats

Indexed keywords

BOSENTAN; CYCLOSPORIN A; ENDOTHELIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; FEMALE; GRAFT REJECTION; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MARMOSET; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0030010924     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.27.6.1341     Document Type: Article

References (35)

1. Curtis JJ. Cyclosporine and posttransplant hypertension. J Am Soc Nephrol. 1992;2:S243-S245.
2. Luke RG. Essential hypertension: a renal disease? Hypertension. 1993;21:380-390.
3. Sturrock NDC, Struthers AD. Hormonal and other mechanisms involved in the pathogenesis of cyclosporin-induced nephrotoxicity and hypertension in man. Clin Sci. 1994;86:1-9.
4. Gallego MJ, Lopez-Farr A, Riesco A, Monton M, Grandes SM, Barat A, Hernando L, Casado S, Caramelo CA. Blockade of endothelium-dependent responses in conscious rats by cyclosporin A: effect of L-arginine. Am J Physiol. 1993;264:H708-H714.
5. Gotze S, Auch-Schwelk W, Bossaller C, Thelen J, Fleck E. Calcium entry blockade may prevent cyclosporin A-induced hypersensitivity to angiotensin II and endothelial dysfunction in the rat aorta. Eur Heart J. 1993;14:104-110.
6. Fung JJ, Starzl TE. FK 506 in solid organ transplantation. Transplant Proc. 1994;26:3017-3020.
7. Takeda Y, Yoneda T, Ho Y, Miyamori I, Takeda R. Stimulation of endothelin mRNA and secretion in human endothelial cells by FK 506. J Cardiovasc Pharmacol. 1993;22:S310-S312.
8. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasocon-strictor peptide produced by endothelial cells. Nature. 1988;332: 411-415.
9. Haynes WG, Webb DJ. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci. 1993; 84:485-500.
10. Levin ER. Endothelins. N Engl J Med. 1995;333:356-362.
11. Takeda Y, Miyamori I, Yoneda T, Takeda R. Endothelin-1 release from the mesenteric arteries of cyclosporine-treated rats. Eur J Pharmacol. 1992;213:445-447.
12. Iwai J, Kanayama Y, Negoro N, Okamura M, Takeda T. Gene expression of endothelin receptors in aortic cells from cyclosporine-induced hypertensive rats. Clin Exp Pharmacol Physiol. 1995;22: 404-409.
13. Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest. 1991; 88:310-314.
14. Phillips PA, Rolls KA, Burrell LM, Casley D, Aldred KL, Hardy KJ. Vascular endothelin responsiveness and receptor characteristics in vitro and effects of endothelin receptor blockade in vivo in cyclosporin hypertension. Clin Exp Pharmacol Physiol. 1994;21: 223-226.
15. Clozel M, Breu V, Gray GA, Kalina B, Loffler B-M, Burri K, Cassal J-M, Hirth G, Muller M, Neidhart W, Ramuz H. Pharmacological characterisation of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994;270: 228-235.
16. Clozel J-P, Fischli W. Cyclosporin-induced hypertension in marmosets: a new model of hypertension sensitive to angiotensinconverting enzyme inhibition. J Cardiovasc Pharmacol. 1989;14: 77-81.
17. Carrier M, Tronc F, Stewart D, Mattel S, Pelletier LC. Blockade of cyclosporine-induced vasoconstriction by the calcium channel blocker diltiazem in dogs. J Thorac Cardiovasc Surg. 1993;106: 487-490.
18. Fozard JR, Menninger K, Schoeffter P. Cardiovascular effects of cyclosporine A and OG 37-325 after chronic administration to conscious rats: role of endothelin. Transplant Proc. 1994;26: 3006-3009.
19. Grieff M, Loertscher R, Shohaib SA, Stewart DJ. Cyclosporin-induced elevation in circulating endothelin-1 in patients with solid organ transplants. Transplantation. 1993;56:880-884.
20. Haas GJ, Wooding-Scott M, Binkly PF, Myerowitz PD, Kelley R, Cody RJ. Effects of successful cardiac transplantation on plasma endothelin. Am J Cardiol. 1993;71:237-240.
21. Pei Y, Chan C, Cattran D, Cardella C, Zaltzman J, Lopez M, Tong J, Schachter R, Maurer J. Sustained vasoconstriction associated with daily cyclosporine dose in heart and lung transplant recipients: potential role of endothelin. J Lab Clin Med. 1995;125:113-119.
22. Sturrock NDC, Lang CC, MacFarlane LJ, Dockrel MEC, Ryan M, Webb DJ, Struthers AD. Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyelosporin therapy in males. J Hypertens. 1995;13:667-673.
23. Takeda Y, Miyamori I, Yoneda T, Takeda R. Increased concentration of endothelin messenger RNA in the mesenteric arteries of cyclosporin-induced hypertensive rats. Am J Hypertens. 1993;6: 427-430.
24. Clozel M, Breu V, Burri K, Cassal J-M. Fischli W, Gray GA, Hirth G, Loffler B-M, Muller M, Neidhardt W, Ramuz H. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993;365:759-761.
25. Phillips PA, Risvanis J, Aldred KA, Burrell LM, Bartholomeusz B. Differential effects of nonpeptide endothelin receptor antagonist (bosentan) in rat vasculature and liver. Clin Sci. 1995;89:575-579.
26. Bloom IT, Bentley FR, Garrison RN. Acute cyclosporine-induced renal vasoconstriction is mediated by endothelin-1. Surgery. 1993; 114:4811-488.
27. Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest. 1993;91:2144-2149.
28. Kon V, Hunley TE, Fogo A. Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Transplantation. 1995;60:89-95.
29. Iwasaki S, Homma T, Kon V. Site specific regulation in the kidney of endothelin and its receptor subtypes by cyclosporine. Kidney Int. 1994;45:592-597.
30. Bird JE, Moreland S, Waldron TL, Powell JR. Antihypertensive effects of a novel endothelin-A receptor antagonist in rats. Hypertension. 1995;25:1191-1195.
31. Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension. 1995;25:1135-1143.
32. Douglas SA, Gellai M, Ezekiel M, Feuerstein GZ, Elliot JD, Ohlstein EH. Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670. Hypertension. 1995;25: 818-822.
33. Ohlstein EH, Douglas SA, Ezekiel M, Gellai M. Antihypertensive effects of the endothelin receptor antagonist BQ 123 in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993;22: S321-S324.
34. Li J-S, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension. 1995;25:495-500.
35. Schmitt R, Belz GG, Fell D, Lebmeier R, Prager G, Stahnke PL, Sittner WD, Karworth A, Jones CR. Effects of a novel endothelin receptor antagonist bosentan in hypertensive patients. In: Abstracts of the 7th European Meeting on Hypertension; June 9-12; Milan, Italy. Abstract 747.